cas 13796-49-1|| where to buy 2-[(1R,3aS,3bS,9aS,9bR,11aS)-9b-bromo-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

Nom du produit:2-[(1R,3aS,3bS,9aS,9bR,11aS)-9b-bromo-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

IUPAC Name:2-[(1R,3aS,3bS,9aS,9bR,11aS)-9b-bromo-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate

: CAS：13796-49-1; Formule moléculaire：C24H31BrO6; Pureté：95%+

: Numéro de catalogue：CM1046906; Poids moléculaire：495.41

Unité d'emballage	Stock disponible	Prix($)	Quantité

Demande: sales@chemenu.com

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 13796-49-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

Détails du produit

: N° CAS:13796-49-1; Formule moléculaire:C24H31BrO6; Point de fusion:-; Code SMILES:CC1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3(C(C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)Br)C; Densité:

: Numéro de catalogue:CM1046906; Poids moléculaire:495.41; Point d'ébullition:; N° Mdl:; Stockage:

Column Infos

: Vamorolone; Dec 18, 2023, AGAMREE (vamorolone) has been approved in the European Union (EU) for the treatment of DMD in patients 4 years of age and older.
Duchenne muscular dystrophy (DMD) is a genetic muscle disease. And The feature is contraction-induced myofibre injury and inflammation. Researchers found that NF-κB signaling is active in dystrophin deficient muscle. Therefore, Inhibiting NF-κB is a potent strategy for the treatment of DMD. Vamorolone is an investigational drug that was developed as a novel dissociative steroidal anti-inflammatory. This means that its chemical profile is such that it shows chemical separation of efficacy (clinical benefit) from some safety concerns (side effect profiles) typically seen with corticosteroids.
AGAMREE is the only approved medication in the EU for treating DMD, and the first DMD treatment approved in both the U.S. and EU.

Formulaire de demande

Détails du produit

Column Infos

Related Products